Header Logo

Connection

EUGENIE S KLEINERMAN to Imatinib Mesylate

Back to Details
This is a "connection" page, showing publications EUGENIE S KLEINERMAN has written about Imatinib Mesylate.
EUGENIE S KLEINERMAN
Connection Strength
0.016
Imatinib Mesylate
  1. Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy. Cancer. 2010 Aug 15; 116(16):3892-902.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.